Fluvoxamine for COVID-19?

被引：0
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2021年 / 63卷 / 1623期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：69 / 70
页数：2
相关论文
共 7 条
  • [1] [Anonymous], 2020, MED LETT DRUGS THER, V62, P186
  • [2] [Anonymous], 2021, MED LETT DRUGS THER
  • [3] Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
    Hashimoto, Kenji
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2021, 271 (02) : 249 - 258
  • [4] Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial
    Lenze, Eric J.
    Mattar, Caline
    Zorumski, Charles F.
    Stevens, Angela
    Schweiger, Julie
    Nicol, Ginger E.
    Miller, J. Philip
    Yang, Lei
    Yingling, Michael
    Avidan, Michael S.
    Reiersen, Angela M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (22): : 2292 - 2300
  • [5] NIH, FLUV EARL TREATM COV
  • [6] Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis
    Rosen, Dorian A.
    Seki, Scott M.
    Fernandez-Castaneda, Anthony
    Beiter, Rebecca M.
    Eccles, Jacob D.
    Woodfolk, Judith A.
    Gaultier, Alban
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (478)
  • [7] Seftel D., 2021, OPEN FORUM INFECT DI
1